Vivaglobin developed by Cambridge Antibody Technology Group plc and Abbott Laboratories is indicated for the treatment of patients with primary immunodeficiency (PI). Primary immunodeficiency are a group of genetic disorders that cause a malfunction in part or all of the immune system, keeping the patient from fighting off infections caused by common everyday germs. For individuals with primary immunodeficiency many of them Childrens, infections may not improve with treatment as expected, and may keep returning. As a result, patients may face frequent rounds of antibiotics or be hospitalized for treatment. Repeated infections can lead to organ destruction, which, over time, can become life threatening. In some severe cases of primary immunodeficiency, infections may result in a patient being hospitalized repeatedly. Several infections, such as meningitis, may even result in death.

Vivaglobin delivers treatment directly under the skin via a small, portable pump, offering a safe and effective alternative to intravenous infusions of immunoglobulin, a life-sustaining therapy that has to be converted into the standard care of therapy for the people living with PI. Vivaglobin represents a new treatment option for patients who suffer intolerable side effects from whose veins are difficult to access, such as small children.

As with all immune globulin (Ig) products, patients getting Ig therapy for the first time, receiving a new product, or not having received Ig therapy within the preceding eight weeks may be at risk for developing reactions including fever, chills, nausea, and vomiting. On rare occasions, these reactions may direct to shock. Such patients should be monitored in clinical surroundings during the initial administration.